Targeting cancer with antibody-drug conjugates: Promises and challenges

Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved ten ADCs, namely Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Poli...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Alexis Q. Dean, Shen Luo, Julianne D. Twomey, Baolin Zhang
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Taylor & Francis Group 2021-01-01
Reeks:mAbs
Onderwerpen:
Antibody–drug conjugate (adc)
monoclonal antibody (mAb)
cytotoxic payload
bioconjugation
cancer therapy
analytics
Online toegang:https://www.tandfonline.com/doi/10.1080/19420862.2021.1951427
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items